Related Experiment Videos
Hydroxyurea in children: present and future
1Department of Hematology/Oncology and the Sickle Cell Center, Children's Hospital Oakland, CA 94609, USA.
Insights
Hydroxyurea (HU) shows promise in treating sickle cell disease (SCD) in children by improving hemoglobin levels and preventing organ damage. Long-term safety studies are needed to address potential risks in pediatric patients.
Area of Science:
- Pediatric Hematology
- Pharmacology
- Sickle Cell Disease Research
Background:
- Sickle cell anemia (SCD) causes progressive organ damage in children.
- Hydroxyurea (HU) is a potential therapeutic agent for managing SCD complications.
- Early intervention with HU in infants may alter disease progression and phenotype.
Purpose of the Study:
- To assess the efficacy of hydroxyurea (HU) in preventing complications and organ damage in children with sickle cell disease (SCD).
- To evaluate the potential of HU to inhibit organ dysfunction and alter the clinical phenotype of SCD in infants.
- To examine the impact of HU on hemoglobin F (HbF) levels and red blood cell/endothelial adhesion receptors.
Main Methods:
- Review of six pediatric trials involving severely ill SCD patients treated with standard HU doses.
- Analysis of reported changes in HbF, mean corpuscular volume, and hemoglobin levels.
- Consideration of ongoing and planned pediatric multicenter trials.
Main Results:
- Consistent clinical response to HU observed in pediatric SCD patients.
- Significant improvements in HbF and mean corpuscular volume reported across studies.
- Mild to marked increases in hemoglobin levels noted with HU treatment.
Conclusions:
- Hydroxyurea (HU) demonstrates consistent efficacy in improving hematological parameters and clinical response in children with sickle cell disease (SCD).
- Early initiation of HU in infants may offer significant benefits in preventing organ damage and altering disease trajectory.
- Further long-term studies are crucial to evaluate the safety profile of HU, including risks like carcinogenesis and growth retardation, in pediatric populations.
Abstract:
Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage. The possibility of treating infants with sickle cell disease (SCD) to inhibit the development of organ dysfunction may be the most important future use of HU. The possibility even exists that instituting HU in the neonate may stop the fetal-to-adult globin chain switch and thus markedly change the clinical phenotype of SCD. Recent data suggest HU may also be especially beneficial in children not only by increasing hemoglobin F (HbF), but also by altering the adhesive receptors expressed on red blood cells and vascular endothelium, further increasing the possibility that vasculopathy can be prevented. Six pediatric trials that included small numbers of severely ill patients have been reported recently. All patients received relatively standard HU doses. All studies reported a significant improvement in HbF and mean corpuscular volume and a mild to marked increase in hemoglobin. The clinical response to HU in children with SCD seems to be consistent. The National Institutes of Health pediatric multicenter trial should help answer the question of short-term HU toxicity; however, questions remain concerning long-term risks, such as carcinogenesis, gametogenesis, marrow toxicity, growth retardation, and chromosomal damage. Long-term studies are needed to answer these questions. The future treatment of most children with SCD with HU alone or in combination with other agents looks promising, and long-term trials are warranted.